What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
The Bioavailability of IV Methylprednisolone and Oral Prednisone in Multiple Sclerosis
Neurol 63:1079-1080, Morrow,S.A.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Double-Blind, Randomized, Placebo-Controlled Study of Oral, High-Dose Methylprednisolone in Attacks of MS
Neurol 51:529-534, Sellebjerg,F.,et al, 1998
Randomized Trial Comparing Two Different High Doses of Methylprednisolone in MS, A Clinical and MRI Study
Neurol 50:1833-1836, Oliveri,R.L.,et al, 1998
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Amelioration of Flulike Symptoms at the Onset of Interferon B-1b Therapy in Multiple Sclerosis by Low-Dose Oral Steriods is Related to a Decrease in Interleukin-6 Induction
Ann Neurol 44:682-685, Martinez-Caceres,E.M.,et al, 1998
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
Randomised Trial of Oral and Intravenous Methylprednisolone in Acute Relapses of Multiple Sclerosis
Lancet 349:902-906, 8931997., Barnes,D.,et al, 1997
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Megadose Corticosteroids in Multiple Sclerosis
Neurol 44:1-4, Kupersmith,M.J.,et al, 1994
Oral Megadose Methylprednisolone Therapy in a Pt with Chronic Progressive MS
Neurol 43:230, Gucuyener,K.,et al, 1993
Methylprednisolone in Multiple Sclerosis:A Comparison of Oral with Intravenous Therapy at Equivalent High Dose
JNNP 56:1219-1220, Alam,S.M.,et al, 1993
A Correlative Triad of Gadolinium-DTPA MRI, EDSS, & CSF-MBP in Relapsing MS Treated with High-Dose Intravenous Methylprednisolone
Neurol 42:63-67, Barkhof,F.,et al, 1992
Consensus and Controversy in Neurologic Practice, The Case of Steroid Treatment in Multiple Sclerosis
Arch Neurol 46:322, Menken,M., 1989
Quantitative Magnetic Resonance Imaging in Multiple Sclerosis:The Effect of High Dose Intravenous Methylprednisolone
JNNP 52:14-17, Kesselring,J.,et al, 1989
A Referendum on Clinical Trial Research in Multiple Sclerosis:Opinion of Jekyll Island Workshop
Neurol 39:977-981, Noseworthy,J.H.,et al, 1989
Relative Efficacy of Intravenous Methylprednisolone and ACTH in the Treatment of Acute Relapse in MS
Neurol 39:969-971, Thompson,A.J.,et al, 1989
A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Intrathecal Baclofen for Severe Spinal Spasticity
NEJM 320:1517-1521, 1553-15551989., Penn,R.D.,et al, 1989
Intrathecal Baclofen for Long-Term Treatment of Spasticity:A Multi-Centre Study
JNNP 52:933-939, Ochs,G.,et al, 1989
Methylprednisolone and Multiple Sclerosis
Arch Neurol 45:669-670, Compston,A., 1988
Dangers from Methylprednisolone Acetate Therapy by Intraspinal Injection
Arch Neurol 45:804-806, Nelson,D.A., 1988
Total Lymphoid Irradiation in Multiple Sclerosis:Blood Lymphocytes & Clinical Course
Ann Neurol 22:634-638, Cook,S.D.,et al, 1987